Eltze M, König H, Ullrich B, Grebe T
Department of Pharmacology, Byk Gulden, D-78467, Konstanz, Germany.
Eur J Pharmacol. 2001 Mar;415(2-3):265-76. doi: 10.1016/s0014-2999(01)00835-4.
The potency of the putatively alpha(1B)-adrenoceptor selective drug, 1-[biphenyl-2-yloxy]-4-imino-4-piperidin-1-yl-butan-2-ol (AH11110A), to antagonize contraction upon stimulation of alpha(1A)-adrenoceptors in rat vas deferens and rat perfused kidney, alpha(1B)-adrenoceptors in guinea-pig spleen, mouse spleen and rabbit aorta, and alpha(1D)-adrenoceptors in rat aorta and pulmonary artery was evaluated and compared to that of a number of subtype-discriminating antagonists. N-[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxamide (Rec 15/2739) and (+/-)-1,3,5-trimethyl-6-[[3-[4-((2,3-dihydro-2-hydroxymethyl)-1,4-benzodioxin-5-yl)-1-piperazinyl]propyl]amino]-2,4(1H,3H)-pyrimidinedione (B8805-033) were confirmed as selective for alpha(1A)-adrenoceptors, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY 7378), 8-[2-(1,4-benzodioxan-2-ylmethylamino)ethyl]-8-azaspiro[4.5]decane-7,9-dione (MDL 73005EF), and cystazosin were found to be selective for alpha(1D)-adrenoceptors, whereas spiperone was weakly selective for alpha(1B)-over alpha(1A)-adrenoceptors. However, from the functional affinity profile obtained for AH11110A at alpha(1A)-adrenoceptors (pA(2)=6.41 in rat vas deferens), alpha(1B)-adrenoceptors (pA(2)=5.40-6.54) and alpha(1D)-adrenoceptors (pA(2)=5.47-5.48), the affinity and presumed selectivity previously obtained for AH11110A in radioligand binding studies at native alpha(1B)- and cloned alpha(1b)-adrenoceptors (pK(i)=7.10-7.73) could not be confirmed. Additionally, AH11110A enhanced the general contractility of rat vas deferens, produced a bell-shaped dose-response curve of vasodilation in perfused rat kidney, and its antagonism in most other tissues was not simply competitive. The affinity of AH11110A for prejunctional alpha(2)-adrenoceptors in rabbit vas deferens (pA(2)=5.44) was not much lower than that displayed for alpha(1)-adrenoceptor subtypes, revealing that AH11110A, besides alpha(1)-adrenoceptors, also interacts with alpha(2)-adrenoceptors, and thus may be unsuitable for alpha-adrenoceptor subtype characterization, at least in smooth muscle containing functional studies.
对假定的α(1B)-肾上腺素能受体选择性药物1-[联苯-2-基氧基]-4-亚氨基-4-哌啶-1-基丁-2-醇(AH11110A)在大鼠输精管和大鼠灌注肾中拮抗α(1A)-肾上腺素能受体刺激所致收缩、豚鼠脾脏、小鼠脾脏和兔主动脉中α(1B)-肾上腺素能受体以及大鼠主动脉和肺动脉中α(1D)-肾上腺素能受体的效力进行了评估,并与多种亚型区分拮抗剂进行了比较。N-[3-[4-(2-甲氧基苯基)-1-哌嗪基]丙基]-3-甲基-4-氧代-2-苯基-4H-1-苯并吡喃-8-甲酰胺(Rec 15/2739)和(+/-)-1,3,5-三甲基-6-[[3-[4-((2,3-二氢-2-羟甲基)-1,4-苯并二噁英-5-基)-1-哌嗪基]丙基]氨基]-2,4(1H,3H)-嘧啶二酮(B8805-033)被确认为对α(1A)-肾上腺素能受体具有选择性,8-[2-[4-(2-甲氧基苯基)-1-哌嗪基]乙基]-8-氮杂螺[4.5]癸烷-7,9-二酮(BMY 7378)、8-[2-(1,4-苯并二噁烷-2-基甲基氨基)乙基]-8-氮杂螺[4.5]癸烷-7,9-二酮(MDL 73005EF)和西他唑嗪被发现对α(1D)-肾上腺素能受体具有选择性,而螺哌隆对α(1B)-肾上腺素能受体的选择性略高于α(1A)-肾上腺素能受体。然而,从AH11110A在α(1A)-肾上腺素能受体(大鼠输精管中pA(2)=6.41)、α(1B)-肾上腺素能受体(pA(2)=5.40 - 6.54)和α(1D)-肾上腺素能受体(pA(2)=5.47 - 5.48)上获得的功能亲和力谱来看,先前在天然α(1B)-和克隆α(1b)-肾上腺素能受体的放射性配体结合研究中为AH11110A获得的亲和力和假定的选择性(pK(i)=7.10 - 7.73)无法得到证实。此外,AH11110A增强了大鼠输精管的总体收缩性,在灌注大鼠肾中产生了钟形的血管舒张剂量反应曲线,并且其在大多数其他组织中的拮抗作用并非简单的竞争性。AH11110A对兔输精管中节前α(2)-肾上腺素能受体的亲和力(pA(2)=5.44)并不比其对α(1)-肾上腺素能受体亚型的亲和力低很多,这表明AH11110A除了与α(1)-肾上腺素能受体相互作用外,还与α(2)-肾上腺素能受体相互作用,因此至少在包含功能研究的平滑肌中可能不适用于α-肾上腺素能受体亚型的表征。